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ABSTRACT
Staphylococcus aureus was identiﬁed as the cause
of acute childhood osteomyelitis in 19 patients. A
single clone of community-acquired methicillin-
resistant S. aureus (MRSA) carrying the type IV
mecA staphylococcal cassette chromosome and
the Panton–Valentine leukocidin (PVL) genes was
isolated from ﬁve patients. Among the remaining
14 patients, two methicillin-sensitive S. aureus
(MSSA) isolates were PVL-positive. The maximal
erythrocyte sedimentation rate and C-reactive
protein values, and the time required for normal-
isation, were signiﬁcantly different in patients
with PVL-positive strains (MRSA and MSSA),
suggesting that the production of PVL is an
important factor that contributes to the course of
the disease.
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Staphylococcus aureus remains the prevalent organ-
ism causing acute osteomyelitis (AO), with an
increasing occurrence of methicillin-resistant
S. aureus (MRSA) strains being associated with
musculo-skeletal infections in children [1,2]. The
prevalence of infections caused by community-
acquired MRSA (CA-MRSA) is also increasing
among children [3]. In a recent multicentre study
in Greece, a unique clone of CA-MRSA producing
Panton–Valentine leukocidin (PVL) was isolated
from skin and soft-tissue infections [4]. During the
last 2 years, these strains have been isolated
increasingly from children with staphylococcal
infections in western Greece (personal unpub-
lished data). The aim of the present study was to
investigate the genetic proﬁles of S. aureus isolates
from cases of AO among children in western
Greece between January 2005 and August 2006.
The phenotypes and genotypes of S. aureus
isolates were determined and correlated with
changes in physical signs and laboratory ﬁndings
for the patients.
The study included all children aged <15 years
who were treated for AO caused by S. aureus in
Karamandaneion Children’s Hospital and the
Department of Paediatrics at the University Hos-
pital of Patras, where all children from western
Greece are referred. Changes in laboratory ﬁnd-
ings, e.g., white blood cell count, erythrocyte
sedimentation rate (ESR), and C-reactive protein
(CRP), were assessed in all patients bi-weekly
during hospitalisation, and weekly during the
follow-up period. Bone scans, magnetic resonance
imaging and X-rays of the affected bones were
performed for all patients in order to conﬁrm the
diagnosis and to assess the severity of the disease.
Blood cultures were performed for all patients,
together with bone tissue cultures when surgical
drainage was necessary.
S. aureus was identiﬁed by standard methods
[5]. Antibiotic susceptibilities were determined by
the disk-diffusion method [6] using BBL disks
(Becton Dickinson, Le Pont de Claix, France) for
cefoxitin, vancomycin, kanamycin, gentamicin,
tobramycin, netilmicin, erythromycin, clindamy-
cin, ciproﬂoxacin, sulphamethoxazole–trimetho-
prim, linezolid and fusidic acid. b-Lactamase
production was tested using nitroceﬁn disks
(BBL; Becton Dickinson), and inducible resistance
to clindamycin was tested using the D-test [6].
MICs of oxacillin were determined by the agar
dilution method [7]. Staphylococcal cassette chro-
mosome (SCC)mec types, agr types and PVL genes
(lukS and lukF) were detected by PCR [8–11].
Clones were delineated following pulsed-ﬁeld gel
electrophoresis of SmaI DNA digests [12,13] and
were compared with clones identiﬁed previously
[4,13].
Statistical analysis was performed using SPSS
v.12.0 software for Windows (SPSS Inc., Chicago,
IL, USA). All clinical and laboratory ﬁndings were
analysed using the Mann–Whitney U-test, Fish-
er’s exact test and the chi-square test.
In total, the two institutions treated 19 patients,
12 males and seven females, for AO caused by
S. aureus (Table 1). No increase in the number of
cases of AO was observed during the study
period. S. aureus was isolated from blood (nine
patients), the affected bone (nine patients), and
from both clinical specimens in one patient. The
median age of the patients was 11 (range 2.0–13.0)
years. With the exception of one patient (no. 11;
Table 1), who presented for treatment 30 days
after the onset of symptoms, all patients were
admitted for therapy 1–7 days (mean ± SD
2.7 ± 1.8 days) after the onset of symptoms.
PVL-producing CA-MRSA strains carrying
SCCmecIV, belonging to agr 3 and to a common
clone C, identical to European CA-MRSA ST80,
were isolated from ﬁve males. All CA-MRSA
isolates were resistant to b-lactams, kanamycin
Table 1. Characteristics of patients with acute osteomyeli-
tis and the properties of the infecting strain
Patient no. Location Gender
Age
(years) Strain PVL
Resistance
pattern
1 Right femur M 4.0 MRSA Positive b-l, K, FA
2 Right spine
of the scapula
M 7.0 MRSA Positive b-l, K, FA
3 Left femur M 8.0 MRSA Positive b-l, K, FA
4 Left tibia M 12.0 MRSA Positive b-l, K, FA
5 Left tibia M 12.0 MRSA Positive b-l, K, FA
6 Right tibia F 12.0 MSSA Positive PG
7 Left ileum
and sacrum
F 13.0 MSSA Positive PG, FA
8 Right femur
and tibia
M 9.0 MSSA Negative None
9 Right ulna M 13.0 MSSA Negative PG
10 Right femur M 12.1 MSSA Negative PG
11 Left distal phalanx F 11.0 MSSA Negative PG
12 Left ﬁbula F 2.0 MSSA Negative PG
13 Right ileum
and sacrum
F 12.4 MSSA Negative None
14 Left humerus F 4.3 MSSA Negative PG
15 Left calcaneus M 8.0 MSSA Negative PG
16 Right acetabulum M 11.3 MSSA Negative PG, E
17 Right ﬁbula M 2.5 MSSA Negative PG, FA
18 Left ﬁbula F 11.0 MSSA Negative PG
19 Right femur M 8.0 MSSA Negative PG
M, male; F, female; b-l, b-lactams; K, kanamycin; FA, fusidic acid; PG, penicillin G
(b-lactamase-positive); E, erythromycin; MRSA, methicillin-resistant Staphylococcus
aureus; MSSA, methicillin-sensitive S. aureus; PVL, Panton–Valentine leukocidin.
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and fusidic acid. MSSA strains exhibiting a
variety of resistance phenotypes and belonging
to different clones were isolated from the remaining
14 patients (Table 1). Two methicillin-sensitive
S. aureus (MSSA) isolates produced PVL. The
most frequent location of AO was the femur and
tibia, followed by the ﬁbula. There was no
obvious primary source of infection for 16 of the
19 patients. Socio-economic standards [14] were
moderate-to-poor for 15 patients, and good for
only four patients.
The maximal ESR and CRP values, and the
time required for normalisation of CRP, were
signiﬁcantly different between patients with
PVL-positive MRSA and those with MSSA
(Table 2). A statistically signiﬁcant difference
was also found between patients with PVL-
positive strains (MRSA and MSSA) and those
with PVL-negative MSSA strains for the max-
imal values of ESR and CRP, as well as for the
time necessary for normalisation of ESR and
CRP values.
The course of the disease was particularly
severe for two patients with PVL-positive MRSA.
For patient no. 1 (Table 1), osteomyelitis in the
metaphysis of the right femur extended to the
entire diaphysis, leading to bone destruction. In
patient no. 2, osteomyelitis in the spine of the
scapula was diagnosed and treatment was initi-
ated. However, the patient’s condition deterior-
ated and multiple foci of pneumonia in both lungs
with pleural effusion developed within 2 days.
All patients received appropriate therapy, as
indicated by the antibiotic susceptibility tests,
and recovered during the follow-up period. Apart
from patient no. 1, who received therapy for
86 days (56 days intravenously), the duration of
treatment for patients with MSSA infection was
41–45 days (21 days intravenously), and for those
with MRSA it was 52–56 days (30 days intraven-
ously) [15,16].
S. aureus is the most common pathogen caus-
ing acute osteomyelitis, and MRSA is emerging
as a new causative agent [1]. In a study
performed in Australia, 9% of cases of AO
were caused by MRSA [1], although molecular
characterisation of the isolates or detection of
PVL production was not reported. A separate
study described the occurrence of primary
sternal osteomyelitis caused by a PVL-negative
CA-MRSA strain carrying SCCmecIV [17]. Five
cases of AO in the present study were caused
by PVL-positive CA-MRSA isolates carrying
SCCmecIV; these belonged to a clone character-
ised previously in Greece [4]. In western Greece,
the prevalence of MRSA among children was
46% and 60% in the ﬁrst and second semesters
of 2005, respectively, and 59% in the ﬁrst
semester of 2006, with a corresponding rate of
PVL-positive isolates among the MRSA isolates
of 70%, 85% and 81%, respectively (personal
unpublished data).
Six cases of chronic childhood osteomyelitis
caused by PVL-positive S. aureus have been des-
cribed, with a higher proportion of patients
developing complications in the PVL-positive
group than in the PVL-negative group [2]. In the
present study, patients with PVL-positive strains
(MRSA and MSSA) showed signiﬁcantly different
laboratory ﬁndings compared with the PVL-neg-
ative group, thereby supporting the hypothesis
that these strains are virulent and capable of
causing deep-seated infections. Clindamycin has
excellent bone and joint penetration, and is a
suitable agent for treatment of osteomyelitis
caused by MRSA when the isolate is fully
Table 2. Clinical and laboratory ﬁndings for osteomyelitis patients in relation to the characteristics of the infecting strains
Variable
MSSA vs. MRSA PVL(–) vs. PVL(+)
MSSA MRSA Statistic PVL(–) PVL(+) Statistical comparison
Males ⁄ females 7 ⁄ 7 5 ⁄ 0 p 0.11a 7 ⁄ 5 5 ⁄ 2 p 0.66a
Fever duration (days) 5.2 ± 4.1 7.2 ± 5.4 z )0.8; p 0.4 5.4 ± 4.4 6.3 ± 4.7 z )0.6; p 0.6
Maximal ESR 75 ± 20 108 ± 16 z )2.5; p 0.0124 70 ± 15 108 ± 16 z )3.3; p 0.0011
Days until ESR
normalisation
18.9 ± 7.7 26.2 ± 3.9 z )1.9; p 0.06 17.3 ± 6.9 27.0 ± 3.9 z )2.7; p 0.006
Maximal CRP (mg ⁄dL) 9.3 ± 6.4 18.8 ± 7.9 z )2.5; p 0.0124 7.9 ± 4.9 18.3 ± 8.0 z )3.0; p 0.0023
Days until CRP
normalisation
8.7 ± 3.6 19.6 ± 8.1 z )2.6; p 0.0083 8.3 ± 3.7 17.1 ± 7.9 z )2.663; p 0.0078
WBC count (103 ⁄mm3) 12.4 ± 4.0 11.3 ± 7.1 z )0.648; p 0.52 11.6 ± 4.3 12.2 ± 6.0 z )0.0; p >0.99
Surgery: yes ⁄no 7 ⁄ 7 4 ⁄ 1 p 0.34a 6 ⁄ 6 5 ⁄ 2 p 0.63a
aFisher’s exact p value.
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; WBC, white blood cell; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive S. aureus;
PVL, Panton–Valentine leukocidin.
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susceptible to this compound [2,16]. None of the
S. aureus isolates in the present study was resist-
ant to clindamycin, and this agent was used for
treatment of all cases, either alone or in combina-
tion with vancomycin.
This is the ﬁrst description of CA-MRSA and
MSSA producing PVL as causative agents of AO.
The ﬁndings reinforce the importance of correctly
identifying bacteria isolated from community-
associated infections and performing susceptibil-
ity tests. Production of PVL appeared to be an
important factor contributing to the course of the
disease. PVL-positive S. aureus can be isolated
from patients with invasive musculo-skeletal
infections, including acute childhood osteomyeli-
tis, as well as from patients with skin and soft-
tissue infections.
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